Early data released for Crinetics's atumelnant in congenital adrenal hyperplasia
22 May 2024
Clinical ResultPhase 2
Crinetics Pharmaceuticals announced on Wednesday that initial results from a small study on atumelnant for the treatment of congenital adrenal hyperplasia (CAH) showed "rapid, profound, and sustained suppression" of androstenedione and 17-hydroxyprogesterone (17-OHP) levels. Results from the Phase II study will be presented at the Endocrine Society’s annual meeting (ENDO) in June.
The study enrolled 10 patients with classical CAH on a stable dose of glucocorticoid replacement for at least six months. They received 80 mg once daily, oral atumelnant for 12 weeks. Key efficacy endpoints included early morning androstenedione and 17-OHP levels. The company reported on the first four participants and said it plans to report on additional patient data at ENDO.
The first four participants, with a median age of 34 years, had baseline morning androstenedione levels ranging from 116 ng/dL to 604 ng/dL and baseline 17-OHP levels that ranged from 4740 ng/dL to 6905 ng/dL. Treatment with atumelnant resulted in "rapid and profound" androstenedione and 17-OHP reductions "within two weeks which were maintained for the duration of therapy," the study said. Throughout the study, androstenedione reductions ranged from 74% to 99% and 17-OHP reductions ranged from 68% to greater than 99%.
"There were no serious or treatment related adverse events and atumelnant was generally well-tolerated. This ongoing study will explore further the safety and efficacy of various doses of atumelnant," the study concluded.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.